CLPTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ClearPoint Neuro, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$9.17+0.10 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $276.63M
- P/E (TTM)
- –
- Dividend yield
- –
ClearPoint Neuro, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $28.75M | $27.37M | $23.86M | $21.22M | $21.34M | $20.28M | $18.63M | $17.28M | $14.22M | $11.61M | $10.60M | $10.42M | 68.0% | +34.8% |
| Neurosurgery navigation and therapy | $19.56M | $17.44M | $14.83M | $13.04M | $12.48M | $11.64M | $10.29M | $9.41M | $8.47M | $8.09M | $8.52M | – | 46.3% | +56.7% |
| Neurosurgery Navigation and Therapy - Disposable Products | $19.56M | $17.44M | $14.83M | $13.04M | $12.48M | $11.64M | $10.29M | – | – | – | – | – | 46.3% | +56.7% |
| Biologics and drug delivery | $18.45M | $19.16M | $19.04M | $18.08M | $18.11M | $17.69M | $17.31M | $17.14M | $16.19M | $15.23M | $13.60M | $11.84M | 43.6% | +1.9% |
| Service and other revenue | $13.53M | $13.24M | $13.11M | $13.11M | $12.26M | $11.95M | $12.76M | $13.15M | $13.85M | $14.55M | $13.35M | $11.90M | 32.0% | +10.4% |
| Biologics and Drug Delivery - Services and License Fees | $11.92M | $11.70M | $11.70M | $11.81M | $11.07M | $10.86M | $11.70M | $12.09M | $12.75M | $13.12M | $11.45M | $9.63M | 28.2% | +7.7% |
| Biologics and Drug Delivery - Disposable Products | $6.53M | $7.45M | $7.34M | $6.26M | $7.03M | $6.83M | $5.61M | $5.05M | $3.44M | $2.11M | $2.15M | $2.21M | 15.4% | -7.2% |
| Capital equipment and software | $4.27M | $4.02M | $3.10M | $3.21M | $3.01M | $2.91M | $3.80M | $3.88M | $3.41M | $2.84M | $1.83M | $1.70M | 10.1% | +42.0% |
| Capital Equipment and Software - Systems and Software Products | $2.66M | $2.48M | $1.69M | $1.92M | $1.82M | $1.81M | $2.74M | $2.82M | $2.35M | $1.84M | $860.00K | $773.00K | 6.3% | +46.2% |
| Capital Equipment and Software - Services | $1.61M | $1.54M | $1.41M | $1.30M | $1.19M | $1.09M | $1.06M | $1.06M | $1.06M | $1.01M | $973.00K | $930.00K | 3.8% | +35.5% |
| Functional neurosurgery navigation and therapy | – | – | – | – | – | – | – | – | – | $8.09M | $8.52M | $8.77M | – | – |
| Functional Neurosurgery Navigation and Therapy - Services | – | – | – | – | – | – | – | – | – | $428.00K | $931.00K | $1.34M | – | – |
| Functional Neurosurgery Navigation and Therapy - Disposable Products | – | – | – | – | – | – | – | – | – | $7.66M | $7.59M | $7.43M | – | – |
| Capital Equipment Related Service Revenue | – | – | – | $1.30M | $1.30M | $1.60M | $2.30M | $2.30M | $2.30M | $2.30M | $1.10M | – | – | – |
By region
From the segment and revenue-disaggregation notes of ClearPoint Neuro's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.